Comprehensive Study Guide on Transfusion Medicine

Principles of Blood Transfusion

• Fundamental guidelines governing blood transfusion clinical practice:

  • Blood transfusion should only be administered when the potential therapeutic benefits clearly outweigh the associated clinical risks.

  • Patients scheduled for elective surgical procedures must have pre-existing anemias evaluated and corrected using appropriate medical interventions prior to surgery.

  • Moderate anemia is not an absolute contraindication for surgery, particularly when the planned procedure is anticipated to correct the primary underlying cause of the anemia.

  • The routine habit of empirical or unnecessary "topping up" transfusions is strongly condemned.

  • Hemoglobin concentration alone is an insufficient indicator for determining the clinical necessity of a blood transfusion.

Blood Components, Plasma Derivatives, and Immune Serum Globulins

• Oxygen-Carrying Blood Components:

  • Red cell concentrate.

  • Leucocyte-poor blood.

  • Frozen-thawed red cells.

• Platelet Products:

  • Platelet-rich plasma (PRP).

  • Platelet concentrate.

• Plasma Products:

  • Fresh frozen plasma (FFP).

  • Cryoprecipitate.

  • Stored plasma (containing clotting factors Factor $X$, Factor $IX$, Factor $XII$, and Factor $VII$).

• Coagulation Factor Concentrates:

  • Factor $VIII$ concentrate.

  • Factor $IX$ concentrate.

• Oncotic Agents:

  • Albumin.

• Immune Serum Globulins:

  • Immune serum globulin (IgG).

  • Hepatitis B immune globulin.

  • Varicella-zoster immune globulin.

  • Rh immune globulin.

  • Tetanus immune globulin.

  • Rabies immune globulin.

  • Rubella immune globulin.

  • Hepatitis A immune globulin.

Indications for Red Cell Transfusion

• Specific clinical indications requiring red blood cell transfusion:

  • Anemia produced by recurrent hemorrhage.

  • Pre-operative transfusion requirements.

  • Severe anemia discovered late in pregnancy.

  • Chronic anemia associated with specific chronic clinical conditions:

  • Leukemia.

  • Aplastic anemia.

  • Malignancies.

  • Chronic Renal Failure (CRF).

Compatibility Testing and ABO Blood Selection

• Definition and Scope of Compatibility Testing:

  • Defined as the in vitro demonstration of serological compatibility between the prospective recipient's (patient's) serum and the donor's red blood cells.

• Standard Cross-Matching Techniques:

  • Saline cross-match performed at room temperature.

  • Saline cross-match performed at $37\,^\circ\text{C}$.

  • Albumin cross-match performed at $37\,^\circ\text{C}$.

  • Indirect Coombs test.

  • Enzyme-assisted cross-matching utilizing Papain.

• ABO Selection Matrix for Blood Transfusion:

  • Recipient Blood Group $O$:

  • First choice donor group: Group $O$.

  • Alternative choice when first choice is unavailable: None.

  • Recipient Blood Group $A$:

  • First choice donor group: Group $A$.

  • Alternative choice when first choice is unavailable: Group $O$.

  • Recipient Blood Group $A$ with anti-$A_1$ antibodies:

  • First choice donor group: Group $A_2$.

  • Alternative choice when first choice is unavailable: Group $O$.

  • Recipient Blood Group $B$:

  • First choice donor group: Group $B$.

  • Alternative choice when first choice is unavailable: Group $O$.

  • Recipient Blood Group $AB$:

  • First choice donor group: Group $AB$.

  • Alternative choice when first choice is unavailable: Group $A$ or Group $B$ (exceptionally Group $O$).

Complications of Blood Transfusion

• Immediate Transfusion Complications:

  • Febrile reactions.

  • Allergic reactions.

  • Circulatory overload.

  • Acute hemolytic reactions.

• Delayed Transfusion Complications:

  • Delayed hemolytic reactions.

  • Transfusion of contaminated or infected blood.

• Transfusion-Transmissible Infectious Pathogens:

  • Viral Pathogens:

  • Hepatitis B Virus (HBV).

  • Hepatitis C Virus (HCV).

  • Human Immunodeficiency Virus (HIV).

  • Cytomegalovirus (CMV).

  • Parasitic and Protozoal Pathogens:

  • Malaria.

  • Chagas disease (Trypanosoma cruzi).

  • Spirochetal and Bacterial Pathogens:

  • Syphilis.

  • Other Rare Transfusion-Transmissible Infections:

  • Human Parvovirus B19.

  • Brucellosis.

  • Epstein-Barr Virus (EBV).

  • Toxoplasmosis.

  • Infectious Mononucleosis.

• Additional Physical, Vascular, and Metabolic Complications:

  • Thrombophlebitis.

  • Air embolism.

  • Hemosiderosis.

  • Complications of massive blood transfusion:

  • Cardiac Arrhythmias (precipitated by excessive citrate, low pH, cold blood, or hyperkalemia).

  • Bleeding diathesis (precipitated by excessive citrate or dilutional thrombocytopenia).

Categories and Clinical Management of Acute Transfusion Reactions

• Category 1: Mild Transfusion Reactions

  • Clinical Signs: Localized cutaneous reactions, Urticaria, Rash.

  • Clinical Symptoms: Pruritus (itching).

  • Etiology: Mild hypersensitivity reactions.

  • Management Protocol:

  • Slow the rate of transfusion.

  • Administer an intramuscular (IM) antihistamine (e.g., chlorpheniramine $0.1\,\text{mg/kg}$ body weight or equivalent).

• Category 2: Moderately Severe Transfusion Reactions

  • Clinical Signs: Flushing, Urticaria, Rigors, Fever, Restlessness, Tachycardia.

  • Clinical Symptoms: Anxiety, Pruritus, Palpitations, Mild dyspnea, Headache.

  • Etiology:

  • Moderate-to-severe hypersensitivity reactions.

  • Febrile non-hemolytic transfusion reactions caused by:

    • Antibodies directed against white blood cells (WBCs) or platelets.

    • Antibodies directed against plasma proteins (including IgA).

    • Bacterial pyrogens or mild bacterial contamination.

  • Management Protocol:

  • Stop the transfusion immediately.

  • Replace the IV infusion set and maintain open intravenous access using normal saline.

  • Send the implicated blood unit along with the attached infusion set, a fresh urine sample, and new blood samples ($1$ clotted sample and $1$ anticoagulated sample) collected from the arm opposite the infusion site to the blood bank with the completed request form for laboratory evaluation.

  • Administer IM antihistamine (e.g., chlorpheniramine $0.1\,\text{mg/kg}$ body weight or equivalent) and oral or rectal antipyretics (e.g., paracetamol $10\,\text{mg/kg}$; $500\,\text{mg} - 1\,\text{g}$ in adult patients). Avoid aspirin in patients with thrombocytopenia.

  • Administer intravenous (IV) corticosteroids and bronchodilators if anaphylactoid features (such as bronchospasm or stridor) develop.

• Category 3: Life-Threatening Transfusion Reactions

  • Clinical Signs: Severe rigors, High fever, Restlessness, Hypotension, Tachycardia, Hemoglobinuria, Unexplained bleeding / Disseminated Intravascular Coagulation (DIC).

  • Clinical Symptoms: Severe anxiety, Chest pain, Dyspnea, Loin or back pain, Severe headache.

  • Etiology:

  • Acute intravascular hemolysis.

  • Severe bacterial contamination and septic shock.

  • Acute fluid overload.

  • Anaphylaxis.

  • Management Protocol:

  • Stop the transfusion immediately. Replace the infusion set completely and maintain IV access with normal saline.

  • Infuse normal saline initially at $20 - 30\,\text{ml/kg}$ to maintain systolic blood pressure. If hypotensive, infuse over $5\,\text{minutes}$ and elevate the patient's legs.

  • Maintain airway patency and supply high-flow oxygen via face mask.

  • Administer adrenaline ($1:1000$ solution) at $0.01\,\text{mg/kg}$ body weight via slow intramuscular injection.

  • Administer IV corticosteroids and bronchodilators if anaphylactoid features (e.g., bronchospasm, stridor) are present.

  • Administer IV diuretics (e.g., frusemide $1\,\text{mg/kg}$ IV or equivalent).

  • Send the blood unit, infusion set, fresh urine specimen, and new blood samples ($1$ clotted and $1$ anticoagulated) drawn from the opposite arm to the laboratory for emergency diagnostic workup.

Delayed Transfusion Reactions and Post-Transfusion Purpura

• Delayed Hemolytic Transfusion Reactions:

  • Onset: Clinical features manifest $5 - 10\,\text{days}$ post-transfusion.

  • Manifestations:

  • Fever.

  • Progressive anemia.

  • Jaundice.

  • Uncommonly, hemoglobinuria.

• Post-Transfusion Purpura (PTP):

  • Definition: A rare, life-threatening complication resulting from red blood cell or platelet concentrate transfusions.

  • Pathophysiology: Mediated by alloantibodies targeted against platelet-specific antigens in the recipient.

  • Patient Population: Highest incidence observed in female patients.

  • Clinical Presentation:

  • Overt physical signs of systemic bleeding.

  • Acute, profound thrombocytopenia occurring $5 - 10\,\text{days}$ post-transfusion, characterized by a platelet count dropping below $100 \times 10^9\,\text{/L}$ (or falling as low as $20 \times 10^9\,\text{/L}$).

Massive Blood Transfusion

• Definition and Volume Thresholds:

  • Defined as the replacement of a patient's total estimated blood volume or greater within a $24\text{-hour}$ period.

  • Adults: Equivalent to or exceeding $70\,\text{ml/kg}$.

  • Pediatric / Infant population: Equivalent to or exceeding $80 - 90\,\text{ml/kg}$.

• Pathophysiology and Prevention of Massive Transfusion Complications:

  • Cardiac Abnormalities:

  • Induced by excess citrate accumulation, severe acidosis (low pH), hypothermia (cold blood), or hyperkalemia.

  • Prevention: Administer $2\,\text{ml}$ of $10\%$ calcium gluconate solution per unit of blood transfused.

  • Acidosis:

  • Prevention: Transfuse fresh blood products whenever possible.

  • Hemostatic Failure:

  • Caused by dilutional coagulopathy and loss of functional platelets/factors due to citrate load.

  • Shock Lung Syndrome / Acute Respiratory Distress Syndrome (ARDS):

  • Pathogenesis: Complex and multifactorial, involving direct alveolar capillary cell toxicity, local DIC, microvascular fluid extravasation, and microvascular embolization by leukocyte/platelet microaggregates present in stored blood.

  • Jaundice.

Exchange Transfusion and Autologous Transfusion

• Exchange Blood Transfusion Indications:

  • Hemolytic Disease of the Newborn (HDN).

  • Sickle Cell Disease complications:

  • Pre-operative preparation.

  • Severe splenic or hepatic sequestration crisis.

  • Severe vaso-occlusive crisis occurring around labor and the puerperium.

  • Central Nervous System (CNS) infarction / stroke.

  • Acute priapism.

  • Acute chest syndrome.

  • Management of fulminant hepatitis or hepatic coma.

  • Acute severe drug toxicity / poisoning.

  • Severe Disseminated Intravascular Coagulation (DIC) in infants.

• Autologous Blood Transfusion Modalities:

  • Intraoperative / Perioperative cell salvage autologous transfusion.

  • Peri-operative acute normovolemic hemodilution.

  • Pre-deposit autologous blood donation.

Plasma Substitutes: Colloids and Crystalloids

• Overview of Plasma Substitutes:

  • Definition: Synthesized or processed crystalloid and colloid solutions designed to restore and maintain intravascular volume in states of acute hemorrhage, hypovolemic shock, thermal burns, and septicemia.

  • Functional Capabilities:

  • Plasma substitutes possess no oxygen-carrying capability.

  • They do not contain functional hemostatic factors.

  • Utilized in acute emergencies to expand intravascular volume and "buy time" while blood cross-matching and component preparation occur.

• Comparative Features of Crystalloids and Colloids:

  • Crystalloid Solutions:

  • Oncotic Capability: Possess no intrinsic colloid oncotic activity.

  • Clinical Advantages: Readily available, easy long-term storage, simple administration, non-immunogenic, non-toxic, and do not suppress hepatic albumin synthesis.

  • Clinical Disadvantages: Lack sustained intravascular oncotic pressure, resulting in rapid extravascular redistribution.

  • Representative Formulations:

    • Normal Saline ($\text{Na}^+$, $\text{Cl}^-$).

    • Ringer's Solution ($\text{Na}^+$, $\text{K}^+$, $\text{Ca}^{2+}$, $\text{Cl}^-$).

    • Hartmann's Solution ($\text{Na}^+$, $\text{K}^+$, $\text{Ca}^{2+}$, $\text{HCO}_3^-$).

  • Colloid Solutions:

  • Oncotic Capability: Provide temporary intravascular colloid oncotic activity.

  • Clinical Advantages: Readily available, straightforward storage, easy administration, sterile (do not transmit viral diseases), supply oncotic expansion, and are relatively inexpensive.

  • Clinical Disadvantages: Short circulatory half-life, weakly immunogenic, potential to impair primary hemostasis, may interfere with blood grouping and serological cross-matching, and may suppress hepatic albumin recovery.

  • Specific Colloid Formulations:

    • Dextrans:

    • Structure: Polysaccharide polymers ranging in molecular weight from $40,000$ to $150,000$ (molecular weight designated as $40 - 15,000$).

    • Storage Parameters: Stored at room temperature with a shelf life of $3 - 5\,\text{years}$.

    • Adverse Effects: Hypotension secondary to vasoactive mediator release, circulatory overload, acute anaphylactoid reactions, acute renal failure (due to tubular/capillary plugging by polysaccharide complexes), and systemic bleeding tendencies.

    • Hydroxyethyl Starch (HES):

    • Structure: Synthetic polymer derived from a waxy starch with an average molecular weight of $$450,000$.

    • Adverse Effects: Uncommonly reported; includes circulatory overload, renal failure, and mild bleeding diathesis.

    • Gelatin (Haemacel):

    • Adverse Effects: Triggers the release of vasoactive substances, especially when rapidly infused.

Artificial Blood and Synthetic Oxygen-Carrying Agents

• Overview:

  • Synthetic oxygen carriers represent experimental pharmaceutical agents created to mimic oxygen transportation without relying on donor red cell transfusions.

• Perfluorochemicals:

  • Chemical Structure: Inert fluorinated hydrocarbons.

  • Oxygen Solubility: High physical solubility for dissolved oxygen, but insoluble in aqueous blood plasma.

  • Prototypical Agent: "Fluosol-DA" (evaluated in animal models and clinical human trials).

  • Adverse Effects: Acute hypotension, Disseminated Intravascular Coagulation (DIC), leucopenia, thrombocytopenia, and direct cellular toxicity toward tissue macrophages.

• Chemically Modified Hemoglobin:

  • Physiological Challenge: Unbound free hemoglobin exhibits an extremely short intravascular half-life and causes severe renal toxicity.

  • Engineering Mechanism: Free hemoglobin is chemically modified (cross-linked or polymerized) to significantly increase its intravascular persistence and improve functional oxygen transport to tissues.